Gilead Sciences

News

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

News

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

News

Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.